Hyphens Pharma Collaborates with Louis Widmer for Cerapro® MED
Hyphens Pharma International Limited is thrilled to announce a significant partnership with Louis Widmer SA for the commercialization of their innovative product, Cerapro® MED Skin Barrier Cream. This agreement enables Louis Widmer to promote and distribute Cerapro® MED in six European countries.
About Cerapro® MED and Its Benefits
Cerapro® MED is a patented cream designed to lower skin pH, approved as a medical device under strict European regulations. This unique formulation offers a groundbreaking solution for atopic dermatitis, a widespread condition affecting individuals in various age groups. By improving skin pH and reinforcing the skin barrier, Cerapro® MED helps alleviate symptoms and enhances the skin's natural defense.
Market Launch Plans
Hyphens Pharma aims to launch Cerapro® MED in six strategic markets, targeting a rollout expected by 2026. The initial focus will be on countries such as Switzerland, Austria, Belgium, the Netherlands, Luxembourg, and Liechtenstein, ensuring that patients across these regions can access this innovative treatment.
Partnership Details with Louis Widmer
Under the terms of this licensing and supply agreement, Hyphens Pharma will receive an upfront payment and ongoing royalties based on the sales of Cerapro® MED. This partnership capitalizes on Louis Widmer's strong foothold in the dermatology space, allowing them to leverage their extensive network of healthcare professionals, including dermatologists and pediatricians.
Commitment to Patient-Centric Solutions
Mr. Lim See Wah, Chairman and CEO of Hyphens Pharma, expressed excitement about this milestone, stating, "This partnership underscores our commitment to innovation and enhancing patient care. By harnessing Louis Widmer's industry expertise, we aim to bring Cerapro® MED to European patients efficiently."
Louis Widmer's Role in the Collaboration
Louis Widmer, established in 1960, has a remarkable history of producing high-quality dermatological products. As part of this collaboration, they are set to integrate Cerapro® MED into their well-regarded Remederm line, which already leads in various European markets for skin care solutions.
About Hyphens Pharma International Limited
As Singapore's leading specialty pharmaceutical and consumer healthcare group, Hyphens Pharma holds a belief that everyone should have access to a better quality of life. The group operates across multiple ASEAN countries, expanding their reach into regions like Malaysia, Vietnam, and Indonesia. Their diverse offerings include proprietary dermatological products and health supplements designed to enhance patient well-being.
The Group's Extensive Reach
Hyphens Pharma's integrated business model consists of several key entities focusing on Pharmaceuticals & Medical Aesthetics, Proprietary Brands, and Digital Platforms. Their emphasis on innovative healthcare solutions aims to fulfill the growing demand for effective treatments in dermatology and beyond.
About Louis Widmer SA
Louis Widmer SA is a Swiss-based cosmetics and pharmaceuticals company known for its dedication to producing effective skincare solutions and dermocosmetic products. Their commitment to sustainability and innovation has positioned them as a trusted brand within the dermatological field.
Frequently Asked Questions
What is Cerapro® MED?
Cerapro® MED is a patented skin barrier cream designed to lower skin pH, aimed at treating atopic dermatitis.
Who is distributing Cerapro® MED in Europe?
Louis Widmer SA will be responsible for the commercialization and promotion of Cerapro® MED in six European nations.
When is the product expected to launch?
The expected launch of Cerapro® MED is targeted for 2026.
What benefits does Cerapro® MED provide?
Cerapro® MED helps restore the skin barrier and supports the skin's natural defense system, making it a beneficial treatment for eczema.
What does the partnership involve?
The partnership includes an upfront fee and royalties on sales for Hyphens Pharma as part of the licensing agreement with Louis Widmer.
